Tasigna (nilotinib) is a chemotherapy drug originally approved to treat Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Tasigna can have serious and life-threatening side effects, including the development of atherosclerosis. When the drug was approved by the U.S. Food and Drug Administration (FDA) in 2007, it carried … [Read more...]
Recent Comments